Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine
Current Treatment Options in Oncology · 2024
DOI: 10.1007/s11864-024-01204-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Sara Arfan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK. Hauptthemen laut MEDLINE: Leiomyosarcoma, Precision Medicine, Genetic Heterogeneity, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: Cancer Research UK, Sarcoma UK, National Institute for Health and Care Research.
Abstract (Originalsprache)
OPINION STATEMENT: Leiomyosarcoma (LMS) is one of the more common subtypes of soft tissue sarcomas (STS), accounting for about 20% of cases. Differences in anatomical location, risk of recurrence and histomorphological variants contribute to the substantial clinical heterogeneity in survival outcomes and therapy responses observed in patients. There is therefore a need to move away from the current one-size-fits-all treatment approach towards a personalised strategy tailored for individual patients. Over the past decade, tissue profiling studies have revealed key genomic features and an additional layer of molecular heterogeneity among patients, with potential utility for optimal risk stratification and biomarker-matched therapies. Furthermore, recent studies investigating intratumour heterogeneity and tumour evolution patterns in LMS suggest some key features that may need to be taken into consideration when designing treatment strategies and clinical trials. Moving forward, national and international collaborative efforts to aggregate expertise, data, resources and tools are needed to achieve a step change in improving patient survival outcomes in this disease of unmet need.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
- The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
- Division of Clinical Studies, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
- Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK. paul.huang@icr.ac.uk.
Förderung
- Cancer Research UK
- Sarcoma UK
- National Institute for Health and Care Research
- Sarah Burkeman Trust
- The Institute of Cancer Research
Zitieren
APA
Arfan, S., Thway, K., Jones, R. L., & Huang, P. H. (2024). Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01204-5
Vancouver
Arfan S, Thway K, Jones RL, Huang PH. Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01204-5
BibTeX
@article{Arfan2024,
author = {Arfan, Sara and Thway, Khin and Jones, Robin L and Huang, Paul H},
title = {Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine},
journal = {Current Treatment Options in Oncology},
year = {2024},
doi = {10.1007/s11864-024-01204-5}
}
EUVIMED